Emyria Ltd (ASX:EMD)'s Michael Winlo tells Andrew Scott about its new ultra pure cannabidiol (CBD) capsule - RX7 - which offers high bio-availability. This opens up the opportunity for the company to pursue prescription registration for indications that require a very high dose of CBD, such as anxiety, epilepsy, fibromyalgia and pain conditions. A Phase 1 trial is expected to kick off later this year.
Emyria launches a new high bio-availability CBD capsule for prescription indications
